You are here:

ceftolozane-tazobactam (Zerbaxa)

Advice

following a full submission:

ceftolozane/tazobactam (Zerbaxa®) is not recommended for use within NHS Scotland.

Indication under review: for the treatment of the following infections in adults:
- Complicated intra-abdominal infections
- Acute pyelonephritis
- Complicated urinary tract infections 

In a phase III, randomised, double-blind study, ceftolozane/tazobactam, in combination with metronidazole, demonstrated non-inferior efficacy to a carbapenem in patients with complicated intra-abdominal infections.

In a phase III, randomised, double-blind study, ceftolozane/tazobactam demonstrated non-inferior efficacy to a quinolone antibiotic in patients with acute pyelonephritis or complicated urinary tract infections.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC. 

Drug Details

Drug Name: ceftolozane-tazobactam (Zerbaxa)
SMC Drug ID: 1146/16
Manufacturer: MSD
Indication: For the treatment of the following infections in adults: - Complicated intra-abdominal infections - Acute pyelonephritis - Complicated urinary tract infections
BNF Category:
Sub Category: 5.1 Antibacterial drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 May 2016

Back